加拿大公开资助的不确定性甲状腺结节分子检测经验
这项在加拿大魁北克5个学术中心开展的多中心前瞻性研究纳入500例Bethesda III或IV且TIRADS 3或4、结节1至4 cm的不确定性甲状腺结节患者,评估ThyroSeq v3的良性呼叫率及其成本效益。结果显示良性呼叫率为72.6%(95% CI,68.5%-76.5%;作者认为在公共医疗体系中该检测具有成本效益并能避免不必要的手术。
要点
- ThyroSeq v3在不确定性甲状腺结节中的良性呼叫率为72.6%(95% CI,68.5%-76.5%;P < .001)。
- 阴性结果患者中99.7%避免了手术,阳性预测值为68.2%(95% CI,58.5%-76.9%)。
核心结论
- 在经充分选择的不确定性甲状腺结节人群中,使用ThyroSeq v3分子检测的良性呼叫率为72.6%,在公共医疗环境中具有成本效益并能避免不必要的手术。
研究设计与样本
- 多中心前瞻性研究,在加拿大魁北克的5个学术中心开展。
- 共纳入500例连续患者,结节为Bethesda III(基于连续2次细胞病理学)或IV且TIRADS 3或4、大小1至4 cm。
- 分子检测于2021年11月至2022年11月间进行;ThyroSeq v3阳性者转诊手术,阴性者计划超声随访至少2年。
主要发现
- 500例患者接受ThyroSeq v3检测,良性呼叫率为72.6%(95% CI,68.5%-76.5%;P < .001)。
- 最终99.7%的阴性结果患者避免了手术。
- ThyroSeq v3的阳性预测值为68.2%(95% CI,58.5%-76.9%)。
关键数值与推荐
- 良性呼叫率定义为ThyroSeq v3阴性结果的不确定性甲状腺结节比例,本研究中为72.6%(95% CI,68.5%-76.5%;P < .001)。
- ThyroSeq v3阳性预测值为68.2%(95% CI,58.5%-76.9%)。
临床怎么用
- ThyroSeq v3阳性患者转诊手术,阴性患者计划超声随访至少2年。
- 作者认为在公共医疗环境中对经充分选择的不确定性甲状腺结节患者使用ThyroSeq v3具有成本效益并能避免不必要的手术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Indeterminate thyroid nodules (ITNs) lead to diagnostic surgeries in many countries. The use of molecular testing (MT) is endorsed by several guidelines, but costs are limitative, especially in public health care systems like in Canada. OBJECTIVES: The primary objective of this work was to evaluate the clinical value of ThyroSeq v3 (TSv3) using benign call rate (BCR) in a real-world practice. The secondary objective was to assess the cost-effectiveness of MT. METHODS: This multicentric prospective study was conducted in 5 academic centers in Quebec, Canada. A total of 500 consecutive patients with Bethesda III (on 2 consecutive cytopathologies) or IV and TIRADS 3 or 4 nodules measuring 1 to 4 cm were included. MT was performed between November 2021 and November 2022. Patients with a positive TSv3 were referred for surgery. Patients with a negative TSv3 were planned for follow-up by ultrasonography for a minimum of 2 years. The BCR, corresponding to the proportion of ITNs with negative TSv3 results, was assessed. RESULTS: A total of 500 patients underwent TSv3 testing, with a BCR of 72.6% (95% CI, 68.5%-76.5%; P < .001). Ultimately, 99.7% of patients with a negative result avoided surgery. The positive predictive value of TSv3 was 68.2% (95% CI, 58.5%-76.9%). The cost-benefit analysis identified that the implementation of MT would yield a cost savings of $6.1 million over the next 10 years. CONCLUSION: The use of MT (TSv3) in a well-selected population with ITNs led to a BCR of 72.6%. It is cost-effective and prevents unnecessary surgeries in a public health care setting.
引用
- Lévesque F, Payne RJ, Beaudoin D, et al. Publicly Funded Molecular Testing of Indeterminate Thyroid Nodules: Canada's Experience. J Clin Endocrinol Metab. 2025. PMID: 38779881. doi:10.1210/clinem/dgae355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。